Vitex negundo extract drives osteogenic signals and bacterial killing in vitro
A leaf aqueous extract from Vitex negundo pushed bone-forming signals upward in an in vitro model while also suppressing bacterial growth, including biofilm formation, in a set of experiments that tied osteogenic biology to antimicrobial activity. The work centered on SaOS-2 osteoblast-like cells and two clinically relevant pathogens, Staphylococcus aureus and Pseudomonas aeruginosa, a pairing that reflects the overlap between skeletal repair and infection control in orthopedic settings.
The extract was profiled by LC/MS and yielded 31 highly active phytocompounds. That chemical complexity matters because bone biology rarely turns on a single pathway; flavonoids, phenolics, and related plant metabolites can influence oxidative stress, cellular signaling, and matrix deposition at the same time. In a tissue environment where inflammation and microbial burden can blunt healing, a material that nudges osteoblast function while suppressing bacteria has obvious biological appeal, even before any translational claims are made.
Antibacterial activity reached bactericidal range against two major pathogens
The antimicrobial signal was clear. Vitex negundo leaf aqueous extract showed marked activity against S. aureus and P. aeruginosa, with minimum inhibitory concentrations of 25 and 100 µg/mL and minimum bactericidal concentrations of 50 and 200 µg/mL, respectively. Biofilm formation fell significantly as well, with P < 0.0001 reported for the inhibition signal.
Biofilm suppression is not a minor laboratory endpoint. Biofilms shield bacteria from host defenses and treatment pressures, and in bone-associated infections they can extend persistence, complicate eradication, and delay recovery. A compound that weakens planktonic growth and the structured biofilm state is therefore doing more than shrinking a culture plate colony count; it is interfering with a protective bacterial phenotype that often makes musculoskeletal infection harder to control.
SaOS-2 viability rose before cytotoxicity appeared at higher doses
On the osteoblast-like cell side, the extract behaved in a concentration-dependent way. Cell viability improved up to 200 µg/mL, while higher concentrations at or above 300 µg/mL reduced viability. After 72 hours of exposure, the IC50 was approximately 500 µg/mL. That pattern suggests a biologically active window rather than a uniformly stimulatory effect, which is common for complex natural products: low-to-moderate exposure can support cell signaling, while higher exposure begins to stress cellular metabolism.
A single sentence captures the dose boundary sharply: the same extract that supported osteoblast-like cells at moderate concentrations became inhibitory at higher ones.
This kind of biphasic behavior is clinically familiar in pharmacology and toxicology. A material that affects redox balance, mitochondrial function, or membrane integrity can promote repair-associated phenotypes in one range and impair them in another. For bone regeneration research, the practical implication is straightforward: any future formulation would need a concentration window that preserves viability while still driving differentiation and matrix production.
Mineralization and osteogenic genes moved in the same direction
The most relevant bone-formation signals tracked in parallel. Alkaline phosphatase activity increased in a dose-dependent manner, rising from 2.41 ± 0.03 in controls to 2.58 ± 0.04 at 200 µg/mL. Mineralized matrix formation widened much more dramatically, from 0.44 ± 0.01 in controls to 3.14 ± 0.11 at 200 µg/mL, with P < 0.0001. Quantitative PCR also showed significant up-regulation of RUNX2 and BGLAP at 100 and 200 µg/mL.
These markers sit at different points in the osteogenic cascade. RUNX2 is a master transcriptional regulator tied to osteoblast differentiation, while BGLAP, also known as osteocalcin, reflects later-stage bone matrix maturation. Elevated alkaline phosphatase supports early matrix mineralization. When those signals rise together, the pattern is consistent with a coordinated push toward osteoblastic maturation rather than a single isolated laboratory effect.
The magnitude of mineralization change is especially notable because matrix deposition is where cellular signaling becomes structural biology. Cells may look viable in culture, but without robust mineralization they are not building a bone-like extracellular scaffold. Here, the extract appeared to stimulate both the machinery that initiates osteogenesis and the downstream process that leaves a mineralized footprint.
Cell-cycle shift and nuclear preservation suggest a reparative state
Microscopy and cell-cycle analysis added another layer. Nuclear morphology remained normal, and the S-phase cell population increased from 21.16% in controls to 25.22% at 200 µg/mL. That shift implies more cells moving through DNA synthesis, a pattern that can accompany proliferative or reparative activity when it is not paired with overt nuclear injury.
In vitro, a preserved nucleus is not cosmetic detail. It is a basic safety readout for cellular integrity. The absence of obvious nuclear distortion, alongside increased S-phase representation, supports the idea that the extract was not simply forcing cells into damage-driven turnover. Instead, the data point toward a more orderly cellular response compatible with growth and differentiation at the tested concentration range.
What the chemistry and biology imply for bone repair research
The most plausible explanation is that the phytochemical mixture in Vitex negundo interacts with redox-sensitive and osteogenic signaling networks at the same time. Bone-forming cells are highly responsive to oxidative state, inflammatory tone, and metabolic stress. Plant-derived compounds often act as mild modulators rather than single-target drugs, which can make them attractive in early bone-healing research where the goal is to encourage differentiation without excessive toxicity.
The antibacterial findings raise a separate but clinically relevant possibility. Orthopedic reconstruction, fracture management, and implant-related care often hinge on the ability to control microbial contamination while supporting tissue repair. A candidate with both osteogenic-associated effects and anti-biofilm activity is conceptually well suited to that problem, provided later work can show reproducibility, mechanism, and safety in more physiologic systems.
Still, the model remains limited to a cell culture setting. SaOS-2 cells are useful for screening but cannot substitute for primary human osteoblasts, mesenchymal stem cells, immune interactions, or the mechanical and vascular environment of living bone. The antibacterial assays also stop short of proving performance in infected tissue, where serum proteins, host defenses, and drug distribution can change the picture substantially.
The next steps are already defined by the data itself: primary human osteoblasts, mesenchymal stem cells, and appropriate in vivo models will be needed to confirm whether the osteogenic-associated response survives outside a simplified laboratory system. Until then, Vitex negundo remains an intriguing dual-activity extract with a biologically coherent profile, but one still anchored firmly in preclinical evidence.